Colorectal Cancer Screening Market to Expand With a CAGR of 5.0% from 2026-2034; High Mortality Rate Due to CRC is Highlighting the Need for CRC Screening Tests

The global colorectal cancer screening market size reached the market valuation USD 18.65 billion in 2025. In 2026, the market anticipates its valuation to be USD 19.50 billion in 2026 to USD 28.86 billion by 2034 at a CAGR of 5.0% from 2026 to 2034. Fortune Business Insights™ presents this information in its report titled, “Colorectal Cancer Screening Market Size, Share & Industry Analysis, By Type (Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), Colonoscopy, and Others), By End-user (Hospitals & Clinics, Clinical Laboratories, Diagnostics Imaging Centers, and Others), and Regional Forecast, 2026-2034”

Colorectal cancer screening has been instrumental in the detection of colorectal cancer as it helps in diagnosing the cancer in asymptomatic and high-risk patients. A 2025’s report by World Health Organization (WHO) has reported that in 2022, around 1.9 million new cases of colorectal cancer and 900,000 deaths were recorded in the same year due to colorectal cancer in the same year. Prevalence of colorectal cancer, investments in the R&D, new product launches, and government initiatives are the major factors for boosting the demand for colorectal cancer screening in the market.

Guardant Health, Inc.’s Commercial Availability of Shield Blood Test to Boost Its Market Position

In August 2024, Guardant Health, Inc. a leading precision oncology company, announced that its Shield Blood Test, recently approved by the U.S. Food and Drug Administration (FDA), is now covered by Medicare and is commercially available in the U.S. as the first FDA-approved blood test for primary colorectal cancer (CRC) screening. Such product launches are set to boost the market position of the company.

High Incidence of Colorectal Cancer is Pushing the Requirement for Proper Screening Tests

One of the leading factors in the colorectal cancer screening market growth is the increasing cases of colorectal cancer. The American Cancer Society, Inc. estimated that in 2025, the number of rectal cancer and colon cancer in U.S. were 46,950 and 107,320, respectively. The deaths occurred due to CRC has heightened the requirement of proper screening tests. The incidence is much higher in the developed nations and is gradually increasing in middle and low-income countries.

Despite their high demand, there are some factors that adversely affects their demand and overall market growth. One of the factors being is risks associated with the procedures. Their invasive nature, bowel preparation, sedation discomfort, and complications will hamper the market growth.

Launching Efficient Product Portfolio By Dominating Market Players Led To Their Dominance

In the colorectal cancer screening market space, Olympus Corporation, Exact Sciences Corporation, and Quest Diagnostics are some of the prominent market players. Out of three, Olympus Corporation and Exact Sciences carry some of the most efficient product portfolio for colonoscopy and cancer screening test. Other players FUJIFILM Holdings Corporation, Laboratory Corporation of America Holdings, and Clinical Genomics Technologies Pty Ltd are strengthening their positions by launching new and technologically advanced products.

List of Key Market Players

• NOVIGENIX SA (Switzerland)
• EIKEN CHEMICAL CO., LTD. (Japan)
• Clinical Genomics Technologies Pty Ltd. (U.S.)
• Exact Sciences Corporation (U.S.)
• Epigenomics AG (Germany)
• bioMérieux, Inc. (France)
• Olympus Corporation (Japan)
• KARL STORZ SE & Co. KG (Germany)
• FUJIFILM Holdings America Corporation (Japan)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/colorectal-cancer-screening-market-101144

Key Industry Development

• August 2025 – Freenome announced an exclusive license agreement with Exact Sciences to advance the commercialization of its colorectal (CRC) blood-based screening test, including the U.S. commercial rights and the underlying technology.

Further Report Findings

• North America’s colorectal cancer screening market has consistently maintained its leading position in 2024 and 2025. The regional market growth is driven by awareness for the condition, compensation policies, and a strong guideline framework. Keeping these factors under consideration, overall market value for the region stood at USD 12.13 billion in 2025. The U.S. market has been the dominant one in the region, making-up for 64% of the global screening sales of the market.
• Europe stands second-largest market for the product with an expected growth rate of 8.3% on the account of stool-based testing in the European countries and presence of government programs. The market in U.K. and Germany reached USD 0.16 billion and 0.38 billion respectively in 2025.
• Colonoscopy is the highest utilized type of screening attributed to incidence of colorectal cancer and its higher accuracy in detecting it. Colonoscopy accounted for 72.2% of the market share.
• In terms of end-user, hospitals and clinics held the highest colorectal cancer screening market share where high patient volume are being diagnosed, driving the demand for stool-based and colonoscopy procedures.

Table of Segmentation